|Dr. William G. Rice||Chairman, Pres & CEO||833.02k||N/A||1959|
|Mr. Gregory K. Chow||Sr. VP, Corp. Sec. & CFO||534.58k||N/A||1973|
|Mr. Ernest Kitt||VP of Devel. & Technical Operations||N/A||N/A||N/A|
|Dr. Daniel Douglas Von Hoff FACP, M.D., F.A.C.P.||Sr. VP of Medical Affairs, Special Advisor & Member of Scientific Advisory Board||N/A||N/A||1948|
|Dr. Stephen B. Howell||Chief Medical Officer||N/A||N/A||1945|
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Aptose Biosciences Inc.’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 10.